Today, 437 million people worldwide have type 1 or type 2 diabetes. New estimates published this month show that three-quarters of a billion people could have the disease by 2045 — and cities are the front line of this challenge. As the growth fast becomes unmanageable for health systems, shortening the lives of millions of urban citizens and constraining economic growth, Novo Nordisk is working with a coalition of major cities to bend the curve on type 2 diabetes. We’re calling for local political and health leaders of all cities to ask what it will take to change the trajectory of the disease in their area and to put into practice the new models that we are forging.